Helmut Pürerfellner

Nov 20, 2024 | onlinelibrary.wiley.com | Jia Liao |Yang Chen |Zhiyu Ling |Helmut Pürerfellner

Introduction Sodium–glucose co-transporter inhibitor (SGLTi), which was initially developed as an antidiabetic drug to treat type 2 diabetes mellitus (T2DM), has been shown as a novel pharmacotherapy for patients with cardiovascular (CV) diseases (CVDs).1 Previous randomized controlled trials (RCTs) have shown favourable CV outcome of SGLTi in patients with heart failure (HF) and renal disease, regardless of T2DM.2-12 Recently, the EMPEROR-Preserved13 and DELIVER14 trials have shown...